WO2022262624A1 - UTILISATION PHARMACEUTIQUE DE β2-MICROGLOBULINE OU D'UN INHIBITEUR DE CELLE-CI - Google Patents

UTILISATION PHARMACEUTIQUE DE β2-MICROGLOBULINE OU D'UN INHIBITEUR DE CELLE-CI Download PDF

Info

Publication number
WO2022262624A1
WO2022262624A1 PCT/CN2022/097744 CN2022097744W WO2022262624A1 WO 2022262624 A1 WO2022262624 A1 WO 2022262624A1 CN 2022097744 W CN2022097744 W CN 2022097744W WO 2022262624 A1 WO2022262624 A1 WO 2022262624A1
Authority
WO
WIPO (PCT)
Prior art keywords
microglobulin
mice
gene
seq
sequence
Prior art date
Application number
PCT/CN2022/097744
Other languages
English (en)
Chinese (zh)
Inventor
王鑫
高月
赵依妮
郑秋阳
郑爽
郎茂菊
Original Assignee
厦门大学
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 厦门大学 filed Critical 厦门大学
Publication of WO2022262624A1 publication Critical patent/WO2022262624A1/fr

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A61K49/0008—Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0603—Embryonic cells ; Embryoid bodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0684—Cells of the urinary tract or kidneys
    • C12N5/0686—Kidney cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPRs]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/70539—MHC-molecules, e.g. HLA-molecules

Definitions

  • the invention belongs to the field of biomedicine and relates to the pharmaceutical application of ⁇ 2-microglobulin or its inhibitor.
  • Down syndrome Down's Syndrome, DS
  • Trisomy 21 is the most common cause of congenital intellectual disability.
  • the cause of Down syndrome is that there is one or part of chromosome 21 in the cells of patients with Down syndrome, which interferes with the normal physiological functions of the cells.
  • People with Down syndrome display a variety of disease symptoms, including intellectual disability, language delays, abnormalities of the immune and endocrine systems, and defects of the skeletal, cardiac, and digestive systems.
  • the developmental delay and mental retardation caused by trisomy 21 are an important reason that affects the quality of life of children with Down syndrome. As they grow older, the cognitive problems of children with Down syndrome at school age will become more prominent.
  • all Down syndrome patients will develop neuropathological features similar to Alzheimer's disease (AD) after the age of 40, and 60% of them will show obvious AD-like dementia symptoms at the age of 65.
  • AD Alzheimer's disease
  • AD Alzheimer's disease
  • Amyloid plaques formed by amyloid ( ⁇ -amyloid, A ⁇ )
  • neurofibrillary tangles Neurofibrillary tangles, NFT
  • B2M ⁇ 2-microglobulin
  • MHCI major histocompatibility complex I
  • B2M can also exist in free form rather than in the form of MHCI complex.
  • B2M With the continuous endocytic cycle of MHCI on the cell membrane surface, B2M can fall off the cell membrane surface and enter the blood system.
  • B2M will aggregate and deposit.
  • B2M amyloid deposits mainly exist in the bone joint area and eventually lead to severe arthritis, fractures and carpal tunnel syndrome.
  • serum and plasma levels of B2M are increased in many disease states, and there is increasing evidence that it is a key component of many infectious, autoimmune, and neoplastic central nervous system (CNS) diseases. useful biomarkers of inflammation.
  • CNS central nervous system
  • NMDA receptors are considered a potential pathogenic feature of a variety of neurological diseases, such as ischemic stroke, traumatic brain injury, Alzheimer's disease, epilepsy, mood disorders, and schizophrenia.
  • NMDA receptors are diverse in subunit composition, biophysical and pharmacological properties, interactions, and subcellular localization. The subunit composition of different central nervous system regions varies during development and in disease states.
  • NMDA receptors play a crucial role in cognitive function, and NMDA receptor-mediated impairment of synaptic function is a typical pathological feature of AD and DS. Therefore, NMDA receptors have always been a research hotspot and drug target in the field of neuropharmacology. Interest in NMDA receptor modulators as therapeutic agents has also increased significantly in recent years.
  • Memantine currently an AD drug approved by the FDA, is a reversible blocker of NMDA-type glutamate receptors, but its mechanism and mode of action are completely different from those of the present invention.
  • GluN1 is an essential subunit of the NMDA receptor, encoded by the human chromosome 9 gene, contains 938 amino acids, and is a three-time transmembrane protein, including N-terminal extracellular segment, C-terminal intracellular segment, transmembrane structure and cell Extracellular loop.
  • glutamate is the most important excitatory neurotransmitter in the brain, in other words, glutamate receptors are also one of the most important neurotransmitter receptors in the brain, which plays a vital role in controlling cognitive functions role.
  • cognitive impairment diseases such as AD and DS, glutamate receptor dysfunction occurs, suggesting that it is possible to restore the patient's cognitive function by interfering with glutamate receptors.
  • B2M plays a role in the development of DS and AD
  • drugs targeting B2M for example, antisense oligonucleotides, antibodies, RNAi, etc.
  • B2M plays a role in the development of DS and AD
  • drugs targeting B2M for example, antisense oligonucleotides, antibodies, RNAi, etc.
  • One aspect of the present invention relates to any one of the items selected from the following (1)-(6) in the preparation of treatment and/or prevention of cognitive impairment caused by Down's syndrome or Alzheimer's disease, especially AD or DS Uses in medicines:
  • nucleic acid construct which contains a polynucleotide for completely knocking out or partially knocking out the ⁇ 2-microglobulin gene; preferably, the polynucleotide is an antisense oligonucleotide, siRNA such as shRNA, or It is guide RNA for CRISPR/Cas9 system;
  • a host cell wherein the polynucleotide encoding ⁇ 2-microglobulin is completely knocked out or partially knocked out; preferably, it contains the nucleic acid construct described in item (3);
  • the use, wherein the drug for inhibiting or blocking the activity of ⁇ 2-microglobulin is an antibody against ⁇ 2-microglobulin (for example, the product number of Abcam Company of the United States is ab214769 or ab175031 antibody); preferably, the antibody is a monoclonal antibody.
  • the use, wherein the drug for inhibiting or reducing the expression level of ⁇ 2-microglobulin gene is selected from antisense oligonucleotides, siRNA such as shRNA, and CRISPR-Cas9
  • antisense oligonucleotides siRNA such as shRNA
  • the guide RNA of the system preferably, the sequence of the antisense oligonucleotide is shown in any one of SEQ ID NOs:6-14.
  • the use wherein the amino acid sequence of the ⁇ 2-microglobulin is shown in SEQ ID NO:1.
  • the purposes, wherein, the sequence of the coding region of the ⁇ 2-microglobulin gene is shown in SEQ ID NO:4.
  • the use wherein the sequence of the non-coding region of the ⁇ 2-microglobulin gene is shown in SEQ ID NO:3 and/or SEQ ID NO:5.
  • the present invention finds and clarifies for the first time that the expression of B2M in the brain tissue and plasma of Dp16 in patients with Down's syndrome and the mouse model of Down's syndrome is significantly increased, and the tail vein injection of B2M can damage the cognitive and synaptic functions of wild-type mice. Furthermore, knockdown of B2m reversed cognitive and synaptic deficits in Dp16 in a mouse model of Down syndrome.
  • the present inventors found that the expression of B2M in the brain of the Alzheimer's disease mouse model (5 ⁇ FAD) showed an age-dependent increase, B2M combined and promoted the oligomerization of amyloid A ⁇ , and overexpression of B2M could increase the expression of 5 ⁇ FAD small Amyloid plaque deposition in the mouse brain, and knocking out B2m can significantly reduce the amyloid plaque deposition in the brain of 5 ⁇ FAD mice, and reverse the synaptic function and cognitive function defects of 5 ⁇ FAD mice. This finding provides a potential drug target for the clinical treatment of Alzheimer's disease and Down's syndrome.
  • B2M the B2M content in the body does not affect normal cognitive functions.
  • the expression of B2M increases abnormally.
  • B2M will cause adverse effects on cognitive function. Therefore, reducing B2M in vivo can play a protective role in cognition when B2M is abnormally increased.
  • Example 4 the inventors found through research including Example 4 that the therapeutic mechanism of the present invention for DS or AD is to enhance synaptic function by affecting NMDA-type glutamate receptors.
  • Another aspect of the present invention relates to any one of the items selected from the following (1)-(6) in the preparation and screening for the treatment and/or prevention of Down's syndrome or Alzheimer's disease, especially AD or DS.
  • nucleic acid construct which contains a polynucleotide for completely knocking out or partially knocking out the ⁇ 2-microglobulin gene; preferably, the polynucleotide is an antisense oligonucleotide, siRNA such as shRNA, or It is guide RNA for CRISPR/Cas9 system;
  • a host cell wherein the polynucleotide encoding ⁇ 2-microglobulin is completely knocked out or partially knocked out; preferably, it contains the nucleic acid construct described in item (3);
  • the use, wherein the drug for inhibiting or blocking the activity of ⁇ 2-microglobulin is an antibody against ⁇ 2-microglobulin (for example, the product number of Abcam Company of the United States is ab214769 or ab175031 antibody); preferably, the antibody is a monoclonal antibody.
  • the use, wherein the drug for inhibiting or reducing the gene expression level of ⁇ 2-microglobulin is selected from antisense oligonucleotides, siRNA such as shRNA, and CRISPR- The guide RNA of Cas9 system;
  • the sequence of described antisense oligonucleotide is as shown in any sequence among SEQ ID NOs:6-14.
  • the use wherein the amino acid sequence of the ⁇ 2-microglobulin is shown in SEQ ID NO:1.
  • the purposes, wherein, the sequence of the coding region of the ⁇ 2-microglobulin gene is shown in SEQ ID NO:4.
  • the use wherein the sequence of the non-coding region of the ⁇ 2-microglobulin gene is shown in SEQ ID NO:3 and/or SEQ ID NO:5.
  • Yet another aspect of the present invention relates to a method for screening drugs for treating and/or preventing cognitive impairment caused by Down syndrome or Alzheimer's disease, especially AD or DS, comprising administering cells or animals to be tested The drug, and the step of detecting ⁇ 2-microglobulin activity or detecting the expression level of ⁇ 2-microglobulin gene;
  • the activity of ⁇ 2-microglobulin is reduced or the expression level of ⁇ 2-microglobulin gene is reduced compared with the control before administration or no administration, it is preliminarily judged that the drug to be tested is an effective candidate drug;
  • the cells are model cells of Down syndrome or Alzheimer's disease
  • the animal is a model animal of Down's syndrome or Alzheimer's disease.
  • the drug to be tested can inhibit or reduce the gene expression level of ⁇ 2-microglobulin, or inhibit or block the activity level of ⁇ 2-microglobulin, it can be used as a candidate drug.
  • the drug to be tested can inhibit or reduce the gene expression level of ⁇ 2-microglobulin, or inhibit or block the activity level of ⁇ 2-microglobulin, it can be used as a candidate drug.
  • the drug to be tested is added to the cells of an isolated mammal such as human or mouse, and cells without the drug to be tested are used as a control.
  • the drug to be tested is administered to a mammal such as a human or a mouse, and whether the target symptom or index is improved is observed or detected.
  • Another aspect of the present invention relates to a method for treating and/or preventing cognitive impairment caused by Down's syndrome or Alzheimer's disease, especially AD or DS, comprising administering to a subject in need or applying cells to effectively Quantitative steps selected from any one of the following items 1-3:
  • the method, wherein the drug that inhibits or blocks the activity of ⁇ 2-microglobulin is an antibody against ⁇ 2-microglobulin; preferably, the antibody is a monoclonal antibody .
  • the method, wherein the drug for completely knocking out or partially knocking out the ⁇ 2-microglobulin gene is a drug for completely knocking out or partially knocking out the ⁇ 2-microglobulin gene
  • the polynucleotide of the gene of protein is an antisense oligonucleotide, siRNA such as shRNA, or guide RNA for CRISPR/Cas9 system;
  • the antisense oligonucleotide The sequence of the acid is shown in any one of SEQ ID NOs: 6-14.
  • Inhibiting the level of ⁇ 2-microglobulin activity in a subject or down-regulating the level of ⁇ 2-microglobulin gene expression in a subject depends on many factors, such as the severity of the condition being treated, the sex, age of the patient or animal , body weight and individual response, as well as the condition and past medical history of the patient to be treated. It is common practice in the art to start at levels lower than that required to obtain the desired therapeutic and/or prophylactic effect and to gradually increase the dosage until the desired effect is obtained.
  • the present invention also relates to any one selected from the following items (1)-(6), which is used for the treatment and/or prevention of cognitive impairment caused by Down syndrome or Alzheimer's disease, especially AD or DS :
  • nucleic acid construct which contains a polynucleotide for completely knocking out or partially knocking out the ⁇ 2-microglobulin gene; preferably, the polynucleotide is an antisense oligonucleotide, siRNA such as shRNA, or It is guide RNA for CRISPR/Cas9 system;
  • a host cell wherein the polynucleotide encoding ⁇ 2-microglobulin is completely knocked out or partially knocked out; preferably, it contains the nucleic acid construct described in item (3);
  • the present invention also relates to any one of the following items (1)-(6), which is used for screening for the treatment and/or prevention of Down syndrome or Alzheimer's disease, especially caused by AD or DS Medications for Cognitive Impairment:
  • nucleic acid construct which contains a polynucleotide for completely knocking out or partially knocking out the ⁇ 2-microglobulin gene; preferably, the polynucleotide is an antisense oligonucleotide, siRNA such as shRNA, or It is guide RNA for CRISPR/Cas9 system;
  • a host cell wherein the polynucleotide encoding ⁇ 2-microglobulin is completely knocked out or partially knocked out; preferably, it contains the nucleic acid construct described in item (3);
  • the drug that inhibits or blocks the activity of ⁇ 2-microglobulin is an antibody against ⁇ 2-microglobulin (for example, the American Abcam company product number is ab214769 or ab175031 antibody); preferably, the antibody is a monoclonal antibody.
  • the drug that inhibits or reduces the expression level of the ⁇ 2-microglobulin gene is selected from siRNA such as shRNA, and guide RNA for the CRISPR-Cas9 system.
  • amino acid sequence of the ⁇ 2-microglobulin is as shown in SEQ ID NO:1.
  • sequence of the coding region of the ⁇ 2-microglobulin gene is as shown in SEQ ID NO:4.
  • sequence of the antisense oligonucleotide is as shown in any one of SEQ ID NOs:6-14.
  • ⁇ 2-microglobulin when referring to the amino acid sequence of ⁇ 2-microglobulin (B2M), it includes the full length of ⁇ 2-microglobulin, and also includes its fusion protein.
  • B2M amino acid sequence of ⁇ 2-microglobulin
  • mutations or variations can be naturally produced or artificially introduced without affecting its biological function.
  • the ⁇ 2-microglobulin is human ⁇ 2-microglobulin.
  • the amino acid sequence of ⁇ 2-microglobulin is shown in SEQ ID NO:1.
  • amino acid sequence (N-terminal to C-terminal) of human B2M protein is as follows:
  • sequence of the ⁇ 2-microglobulin gene is shown in SEQ ID NO:2.
  • the 1st-30th nucleotide is the 5' non-coding region sequence (SEQ ID NO: 3, corresponding to 5'-UTR), and the 31st-390th nucleotide is the B2M coding region sequence (SEQ ID NO: 4 underlined), the 391-943 nucleotides are the 3' non-coding region sequence (SEQ ID NO: 5, corresponding to 3'-UTR).
  • nucleic acid construct defined herein as a single- or double-stranded nucleic acid molecule, preferably refers to an artificially constructed nucleic acid molecule.
  • nucleic acid construct also includes one or more operably linked regulatory sequences.
  • operably linked refers to the functional spatial arrangement of two or more nucleotide regions or nucleic acid sequences.
  • the “operably linked” can be achieved by gene recombination.
  • the term "host cell” refers to the cell into which the vector is introduced, including many cell types as follows, such as prokaryotic cells such as Escherichia coli or Bacillus subtilis, fungal cells such as yeast cells or Aspergillus, such as S2 Drosophila cells or Insect cells such as Sf9, or such as fibroblasts, CHO cells, COS cells, NSO cells, HeLa cells, BHK cells, HEK 293 cells, or animal cells such as human cells.
  • prokaryotic cells such as Escherichia coli or Bacillus subtilis
  • fungal cells such as yeast cells or Aspergillus
  • S2 Drosophila cells or Insect cells such as Sf9
  • fibroblasts CHO cells, COS cells, NSO cells, HeLa cells, BHK cells, HEK 293 cells
  • animal cells such as human cells.
  • vector refers to a nucleic acid delivery vehicle into which a polynucleotide inhibiting a certain protein can be inserted.
  • vectors include: plasmids; phagemids; cosmids; artificial chromosomes such as yeast artificial chromosome (YAC), bacterial artificial chromosome (BAC) or P1-derived artificial chromosome (PAC); phage such as lambda phage or M13 phage and animal viruses.
  • Types of animal viruses used as vectors include retroviruses (including lentiviruses), adenoviruses, adeno-associated viruses, herpesviruses (such as herpes simplex virus), poxviruses, baculoviruses, papillomaviruses, papillary polyoma vacuoles Viruses (such as SV40).
  • retroviruses including lentiviruses
  • adenoviruses such as lentiviruses
  • adeno-associated viruses such as herpes simplex virus
  • poxviruses such as herpes simplex virus
  • baculoviruses such as baculoviruses
  • papillomaviruses such as SV40
  • papillary polyoma vacuoles Viruses such as SV40.
  • a vector may contain various elements that control expression.
  • knockdown of DNA or RNA includes, but not limited to, complete knockout and partial knockout.
  • Complete knockout refers to reducing the level of target DNA or target RNA or the level of the protein it expresses to an almost undetectable level (in fact, generally speaking, it is difficult to knock out 100% of target DNA or target RNA ).
  • Partial knockout refers to the situation where the degree of knockout is greater than zero and less than complete knockout.
  • the object when the object is a cell, it refers to the dose that produces the target effect or exerts the target effect, for example, the dosage in the cell is 1 ⁇ M-100 ⁇ M, 5 ⁇ M-50 ⁇ M, 5 ⁇ M-30 ⁇ M, 5 ⁇ M-25 ⁇ M, 5 ⁇ M-20 ⁇ M, 5 ⁇ M-15 ⁇ M, 5 ⁇ M-10 ⁇ M, 10 ⁇ M-25 ⁇ M, 10 ⁇ M-15 ⁇ M, 1 ⁇ M, 2 ⁇ M, 3 ⁇ M, 4 ⁇ M, 5 ⁇ M, 6 ⁇ M, 7 ⁇ M, 8 ⁇ M, 9 ⁇ M, 10 ⁇ M, 11 ⁇ M, 12 ⁇ M, 13 ⁇ M, 14 ⁇ M, 15 ⁇ M, 50 ⁇ M or 100 ⁇ M, or 1 ⁇ g/mL Or 2 ⁇ g/mL, etc.
  • disease and/or condition refers to a physical state of the subject that is associated with the disease and/or condition of the present invention.
  • subject may refer to patients or other animals, especially mammals, such as humans, dogs, monkeys, cattle, , horse, etc.
  • the concentration unit ⁇ M means ⁇ mol/L
  • mM means mmol/L
  • nM means nmol/L.
  • the dosage of the drug in the cells when referring to the dosage of the drug in the cells, unless otherwise specified, it generally refers to the final concentration of the drug after the drug is added.
  • the present invention provides a new drug target for preventing, treating or improving Alzheimer's disease and Down's syndrome, especially preventing, treating or improving cognitive function impairment caused by Alzheimer's disease or Down's syndrome .
  • Inhibiting or blocking the activity of ⁇ 2-microglobulin, or inhibiting or reducing the expression level of ⁇ 2-microglobulin gene can effectively prevent and treat AD or DS, especially AD or DS cognitive impairment.
  • Figure 1A- Figure 1B Schematic representation of increased expression of B2M in brain tissue and plasma of Down syndrome patients and Down syndrome mice. in:
  • Figure 1A Western blot detection of the expression of B2M in the plasma of Down's syndrome patients and normal people, N (Normal) represents normal controls, D (Down's Syndrome) represents Down's syndrome patients, and the protein band stained with Lichunhong is used as an internal reference.
  • Figure 2A- Figure 2D Schematic representation of increased expression of B2M in brain tissue and plasma of Down's mice. in:
  • Figure 2A The expression of B2M and APP in the hippocampus of Dp16 mice detected by Western blot.
  • FIG. 2C The expression of B2M in the plasma of Ts65Dn mice was detected by immunoblotting, and the protein band stained with Lichunhong was used as an internal reference.
  • Figure 3A- Figure 3H Schematic representation of cognitive function and synaptic plasticity in overexpressed B2M-injured mice. Among them: the data in Figure 3D- Figure 3F were statistically analyzed by unpaired t test; the data in Figure 3G- Figure 3H were statistically analyzed by repeated measures ANOVA. *P ⁇ 0.05; **P ⁇ 0.01. in:
  • Figure 3A Flowchart of the experiment of tail vein injection of B2M protein in C57BL/6J mice, each injection of 4 ⁇ g of B2M protein, three consecutive injections, one day rest, a total of 6 rounds of injections, a total of 24 days. After injection, the Morris water maze test and brain slice long-term potentiation (Long-term potentiation, LTP) recording were performed.
  • LTP long-term potentiation
  • Figure 3B Latency for mice to reach the platform during Morris water maze training.
  • Figure 3C swimming trajectories in the Morris water maze space exploration experiment.
  • the upper graph in Fig. 3C represents the swimming track map of the mice in the PBS group during the platform test, and the lower graph in Fig. 3C represents the swimming track map of the mice in the B2M group during the platform test.
  • Figure 3D Latency of mice reaching the platform for the first time during the Morris water maze platform test.
  • Figure 3E The number of shuttles of mice in the platform area during the Morris water maze platform test.
  • Fig. 3F swimming time of mice in the area of the platform during the Morris water maze platform test.
  • Figure 4A- Figure 4B B2M protein incubation impairs NMDA receptor function.
  • the data in Figure 4A was statistically analyzed by unpaired t test; the data in Figure 4B was statistically analyzed by repeated measures ANOVA. **P ⁇ 0.01. in:
  • Figure 4A Statistical chart of NMDAR/AMPAR ratio, B2M protein (concentration 10 ⁇ g/ml) and ACSF were incubated in WT mouse brain slices for 2 hours; 50 ⁇ M PTX was added to the perfusate to block GABA A receptor ion channels, and Schaeffer collateral rings were recorded NMDAR-EPSCs and AMPAR-EPSCs of pyramidal neurons were evoked with clamping voltages of +40mV and -70mV, respectively.
  • FIG. 4B B2M protein (concentration 10 ⁇ g/ml) and ACSF were incubated with WT mouse brain slices for 2 hours; 50 ⁇ M PTX and 20 ⁇ M CNQX were added to the perfusate to block GABA A receptor and AMPA receptor ion channels, respectively, and Schaeffer collaterals were recorded Loops evoked NMDAR-EPSCs from pyramidal neurons with a clamping voltage of +40 mV, respectively.
  • Figure 5A- Figure 5F Schematic diagrams showing that knocking out B2m improves the cognitive function of Dp16 mice. in:
  • Figure 5A Open field experiment, WT, B2m +/– , Dp16, Dp16; B2m +/– total movement distance in the open field.
  • FIG. 5B T-maze experiment, the number of times mice alternated in the three arms of the T-maze.
  • Figure 5C Latency for mice to reach the platform during Morris water maze training.
  • Figure 5D Morris water maze platform test period, the latency period for mice to reach the platform for the first time.
  • Figure 5E During the Morris water maze platform test period, the swimming time of mice in the area where the platform is located.
  • Figure 6A- Figure 6F Schematic diagrams showing that knocking out B2m improves synaptic function in Dp16 mice. in:
  • Figure 6A Recording LTP of WT, B2m +/- , Dp16, Dp16; B2m +/- mouse hippocampal Schaefer collateral-CA1, the upper curve in Figure 6A represents the baseline and high-frequency stimulation trajectory of LTP.
  • the lower curve in Figure 6A is the LTP recording result.
  • Figure 6E Golgi staining: representation of dendritic spines in the hippocampal CA1 region of WT mice, B2m +/- mice, Dp16 mice, Dp16; B2m +/- mice.
  • the scale bar in the figure is 5 ⁇ m.
  • Figure 6F Statistics of the number of dendritic spines in Figure 6D.
  • Data represent mean ⁇ standard error.
  • Data were statistically analyzed using one-way ANOVA. *P ⁇ 0.05;**P ⁇ 0.01;****P ⁇ 0.0001.
  • Fig. 7A-Fig. 7C Schematic diagram of age-dependent increase of B2M in the brain of AD mice and its localization in A ⁇ amyloid plaques. in:
  • Figure 7A Western blot analysis results of B2M expression in the cerebral cortex tissues of 3, 6, 9, 12, and 15-month-old WT and 5 ⁇ FAD mice.
  • FIG. 7C 2 ⁇ l of adeno-associated virus (AAV) overexpressing B2M-HA was injected into the hippocampus of 2-month-old 5 ⁇ FAD mice by stereotaxic injection, and the mice were anesthetized with 5% chloral hydrate 4 months after the single injection Rats were perfused with phosphate buffered saline, the brain tissue was taken, fixed overnight in 4% paraformaldehyde, dehydrated with 25% and 30% sucrose solution, embedded with OCT, frozen sectioned, and immunofluorescent stained , the dye 4',6-diamidino-2-phenylindole (4',6-diamidino-2-phenylindole, DAPI) labeled cell nuclei, antibody 6E10 labeled A ⁇ and microglial cell marker protein Iba1 antibody labeled microglial Plasma cells were imaged by laser confocal fluorescence microscopy. Scale bar, 100 ⁇ m. Data represent mean ⁇ standard error.
  • AAV
  • Figure 8A- Figure 8E Schematic diagrams showing that overexpression of B2M increases the deposition of A ⁇ amyloid plaques in the brains of AD mice.
  • Fig. 8A-Fig. 8C are the results of immunofluorescence staining after stereotaxic injection of AAV-B2M and control virus in the brain of 6-month-old 5 ⁇ FAD mice.
  • DAPI microglial cell marker protein
  • Figure 8B Statistical results of the number of A ⁇ amyloid plaques (Number of A ⁇ deposition) in the DG region of the hippocampus in Figure 8A. The data were statistically analyzed using the Mann-Whitney test. ns, no significant difference, P>0.05; *P ⁇ 0.05; **P ⁇ 0.01; ***P ⁇ 0.001.
  • Figure 8C Statistical results of the total area of A ⁇ amyloid plaques in the DG region of the hippocampus in Figure 8A. The data were statistically analyzed using the Mann-Whitney test. ns, no significant difference, P>0.05; *P ⁇ 0.05; **P ⁇ 0.01; ***P ⁇ 0.001.
  • Figure 9A- Figure 9D Schematic diagrams showing that knocking out B2m enhances the cognitive function of AD mice.
  • Fig. 9A-Fig. 9C are 6-7 month old WT, B2m +/- , 5 ⁇ FAD, 5 ⁇ FAD; B2m +/– mice Morris water maze (MWM) behavioral results.
  • the data in Figure 9B and Figure 9C were statistically analyzed by one-way ANOVA, and the data in Figure 9D were statistically analyzed by Mann-Whitney test. ns, no significant difference, P>0.05;*P ⁇ 0.05;**P ⁇ 0.01;***P ⁇ 0.001;****P ⁇ 0.0001. in:
  • Fig. 9A Latency to target of mice reaching the platform during Morris water maze (MWM) training period.
  • Figure 10A- Figure 10D Schematic diagram of the reversal of synaptic dysfunction in AD mice by knocking out B2m.
  • Fig. 10A and Fig. 10B are the analysis results of LTP records in CA1 region of brain slices of WT, B2m +/– , 5 ⁇ FAD, 5 ⁇ FAD; B2m +/– mice aged 6-7 months.
  • the data in Figure 10B and Figure 10D were statistically analyzed using one-way ANOVA. ns, no significant difference, P>0.05;*P ⁇ 0.05;**P ⁇ 0.01;***P ⁇ 0.001;****P ⁇ 0.0001. in:
  • Figure 10C Representative images of Golgi staining in hippocampus tissues of 6-7 month old mice.
  • Figure 11A- Figure 11G Schematic diagrams showing that knocking out B2m reduces the deposition of A ⁇ amyloid plaques and the number of microglial cells around the plaques in the brains of AD mice.
  • the data in Fig. 11B, Fig. 11C, Fig. 11D and Fig. 11F were statistically analyzed by Mann-Whitney test. ns, no significant difference, P>0.05; *P ⁇ 0.05; **P ⁇ 0.01; ***P ⁇ 0.001. in:
  • Figure 11A Immunofluorescence staining results of A ⁇ amyloid plaques deposited in the DG region of the hippocampus in the brains of 6-month-old 5 ⁇ FAD, 5 ⁇ FAD; B2m -/- mice.
  • Scale bar 10 ⁇ m.
  • n 5-6 mice per group.
  • Figure 11B The results of statistical analysis of the number of A ⁇ amyloid plaques in the DG region of the hippocampus in Figure 11A.
  • Figure 11C The results of statistical analysis of the area of A ⁇ amyloid plaques in the DG region of the hippocampus in Figure 11A.
  • Figure 11E Immunofluorescent staining of microglial cells surrounding amyloid plaques in the DG region of the hippocampus of 6-month-old 5 ⁇ FAD, 5 ⁇ FAD; B2m –/– mice.
  • Antibody 6E10 labeled A ⁇ and microglial marker protein Iba1 Labeled microglia. Scale bar, 100 ⁇ m. n 5-6 mice per group.
  • FIG. 11F Statistical analysis results of the number of microglia surrounding A ⁇ amyloid plaques in FIG. 11E .
  • FIG. 11G Transmission electron microscopy (TEM) analysis of the effect of B2M protein incubation on A ⁇ 1-42 oligomerization. Scale bar, 100 ⁇ m. Data represent mean ⁇ standard error.
  • FIG. 12A-12E Schematic diagrams of the knockdown efficiency of antisense oligonucleotides targeting human B2M. Among them, the data in Fig. 12C and Fig. 12E were statistically analyzed by ANOVA. ns, no significant difference, P>0.05; *P ⁇ 0.05; **P ⁇ 0.01; ***P ⁇ 0.001; ****P ⁇ 0.0001. in:
  • Figure 12A Schematic diagram of ASO 1-9 sites designed for human B2M mRNA sequence. The full length of B2M mRNA is 943bp, and each ASO sequence is 20-21bp.
  • Example 1 The expression of B2M in the plasma of patients with Down's syndrome increases
  • mice C57BL6 mice were purchased from the Experimental Animal Center of Xiamen University) and 5-6 months-old Down syndrome model mice Dp16 (The Jackson Laboratory, USA) , Cat. No. 013530) the expression levels of B2M in hippocampal tissue and plasma.
  • the mice were anesthetized with 5% chloral hydrate, blood was collected from the heart, and then perfused with phosphate buffer solution to obtain brain tissue.
  • the isolated hippocampal tissue was homogenized, centrifuged at 12,000 rpm for 10 minutes at 4°C, and the supernatant was taken. A 30 ⁇ g protein sample was taken for immunoblotting to detect the expression level of B2M.
  • APP was used as a positive control
  • ⁇ -actin was used as an internal reference gene.
  • the level of B2M in the hippocampus of Dp16 mice was significantly higher than that of WT mice.
  • the collected blood samples were centrifuged at 1000 g for 10 minutes at 4° C., and the supernatant was obtained as plasma.
  • the plasma samples were diluted 20-fold, and 10 ⁇ l was taken for immunoblotting to detect the expression level of B2M, and the protein band stained with Lichunhong was used as an internal reference.
  • the level of B2M in the plasma of Dp16 mice was significantly higher than that of WT mice.
  • Morris water maze test (Morris water maze test) is carried out in a circular water tank (diameter 120 cm), the height of water filling in the water tank is preferably 1 cm higher than the platform, and the temperature of the water in the water tank is set at 22 °C.
  • Four icons of different shapes are pasted in the four directions of the maze arm as spatial positioning reference objects.
  • the platform was 1 cm below the water surface, and then the mice were put into the maze from two water entry points, and the mice were allowed to search for the platform for 60 seconds, and the standard of stopping the experiment was that the mice stayed on the platform for 10 seconds. If the mouse cannot find the platform within 60 seconds, guide it to the location of the platform and allow it to stay on the platform for 10 seconds.
  • mice were tested twice a day, and two different orientations were randomly selected to enter the water, and the interval between two experiments for each mouse was at least 1 hour.
  • the latency time (Latency to target) for the mice to find the platform was recorded for each experiment. 4 consecutive days of learning and training. On the 5th day, the platform was removed, and the platform test was carried out. The mouse was put into the water from the position of the diagonal line of the platform, and allowed to search freely in the water maze for 60 seconds, and the time when the mouse first arrived at the platform was recorded (Latency to target), the number of shuttles on the platform (Target crossings) and the percentage of time spent in the area (%Time in zone).
  • mice injected with B2M and the control group showed no significant difference.
  • the time for the mice injected with B2M to reach the platform for the first time was significantly increased.
  • the number of shuttles on the platform was significantly reduced in the B2M-injected group.
  • the mice in the B2M-injected group spent significantly less time on the platform. It was shown that increasing B2M significantly weakened the cognitive function of mice.
  • the electrophysiological recording of brain slices was performed. After the mice were anesthetized, the brain tissue was quickly removed and cooled in ice-cold and oxygenated artificial cerebrospinal fluid (ACSF), and then transferred to an oscillating microtome for coronal sectioning, with a thickness of 400 ⁇ m. The brain slices were incubated in oxygen-saturated ACSF at 32°C for 1 hour, and then transferred to room temperature for 1 hour. The recording electrodes were placed in the radiation layer of the CA1 region of the Schaffer collateral-commissural pathway, and the stimulating electrodes were placed in the CA3 region.
  • ASF oxygenated artificial cerebrospinal fluid
  • the stimulation intensity was 30% of the maximum field excitatory postsynaptic potential (fEPSP).
  • fEPSP maximum field excitatory postsynaptic potential
  • HFS high-frequency stimulation induced LTP (2 trains of stimulation, Each train consisted of 100 stimulation pulses, each train was separated by 30 s), and the recording lasted for 60 min.
  • B2M protein/normal saline injection 2-3 month old mice were anesthetized with 5% chloral hydrate after weighing, WT mice were 8 ⁇ l/g, the mouse scalp was cut after anesthesia and disinfection, and bilateral CA1 was located through the anterior and posterior bregma (A/P: –2.3mm, M/L: –2mm, D/V: –1.8mm), inject B2M protein at a concentration of 1 ⁇ g/ ⁇ l, and inject 1 ⁇ l/time into bilateral CA1 brain regions, and the injection speed is 0.2 ⁇ l /min, keep the needle for 5 minutes.
  • A/P anterior and posterior bregma
  • M/L –2mm
  • D/V –1.8mm
  • Brain slice electrophysiological recordings were performed 5 days later. After the mice were anesthetized, the brain tissue was quickly removed and cooled in ice-cold and oxygenated artificial cerebrospinal fluid (ACSF), and then transferred to an oscillating microtome for coronal sectioning, with a thickness of 400 ⁇ m. The brain slices were incubated in oxygen-saturated ACSF at 32°C for 1 hour, and then transferred to room temperature for 1 hour. The recording electrodes were placed in the radiation layer of the CA1 region of the Schaffer collateral-commissural pathway, and the stimulating electrodes were placed in the CA3 region.
  • ACSF oxygenated artificial cerebrospinal fluid
  • the stimulation intensity was 30% of the maximum value of the field excitatory postsynaptic potential (fEPSP).
  • fEPSP field excitatory postsynaptic potential
  • Example 4 B2M treatment can weaken NMDA receptor function
  • Electrophysiological recordings were performed on brain slices of 2-3 month old WT mice incubated with B2M protein. The specific operation is as follows:
  • the brain tissue was quickly removed and cooled in ice-cold and oxygenated artificial cerebrospinal fluid (ACSF), and then transferred to an oscillating microtome for coronal sectioning, with a thickness of 400 ⁇ m.
  • the brain slices were incubated in oxygen-saturated ACSF at 32°C for 1 hour, then transferred to room temperature B2M protein (concentration 10 ⁇ g/ml) and ACSF (control group) to incubate WT mouse brain slices for 2 hours, and the stimulating electrodes were placed on the Schaffer In the CA3 region of the collateral-commissural pathway, recording electrodes were clamped to CA1 pyramidal neurons.
  • AMPAR-EPSCs and NMDAR-EPSCs were recorded at clamping voltages of -70mV and +40mV, respectively.
  • the NMDAR/AMPAR ratio was significantly decreased in the B2M incubation compared to the control group.
  • B2M incubation can significantly reduce the amplitude of NMDAR-EPSC in pyramidal neurons in the CA1 region of the hippocampus.
  • B2M may impair excitatory synapse function by weakening NMDA receptor function.
  • B2m gene knockout mice B2m +/– (The Jackson Laboratory, USA, Cat. No. 002087) were mated with Down syndrome model mice Dp16 (The Jackson Laboratory, USA, Cat. No. 013530) to obtain Dp16; B2m +/– mice, and then WT, B2m +/– , Dp16 and Dp16; B2m +/– mice aged 5 to 6 months were subjected to behavioral tests related to learning and memory, including open field, Y-maze and Morris water maze tests.
  • mice Three days before the start of the experiment, touch and touch the mouse once a day, gently grasp the tail of the mouse to pick up the mouse, and let the mouse stay on the hand for 30 seconds; on the day of the experiment, transfer the experimental mouse to the prepared Allow the mice to acclimatize for 30 minutes.
  • Animal behavior experiments are carried out between 9:00a.m.-6:00p.m. every day, and the light intensity in the laboratory is 650lux. Smart Video Tracking Software (Harvard Apparatus, USA) was used for data collection and analysis.
  • the open field test was used to study the voluntary movement ability of mice.
  • the mice were placed in the center of the maze box (40cm(L) ⁇ 40cm(W) ⁇ 40cm(H)), and the mice were allowed to explore freely in the maze for 10 minutes, and the mice were recorded in the open field.
  • the total movement distance (Total distance).
  • WT, B2m +/– , Dp16, Dp16; B2m +/— mice had no significant difference in the total movement distance in the open field, showing that knocking out B2m did not affect the spontaneous movement of mice.
  • mice were placed in the center of the Y-maze (length 30cm, width 6cm, height 15cm), and then the mice were allowed to explore freely in the maze for 5 minutes. All four limbs of the mouse entered the maze arm as the standard for entering the maze arm, and three consecutive entry of the mouse into different maze arms was regarded as a correct autonomous alternate shuttle (Alternation).
  • Dp16 mice had a significantly reduced number of autonomous alternate shuttles (Alternation) in the Y-maze, and after knocking out B2m, Dp16; B2m +/- mice had autonomous alternate shuttles The percentage increased significantly, indicating that knockdown of B2m could reverse working memory in Dp16 mice.
  • Morris water maze test (Morris water maze test) is carried out in a circular water tank (diameter 120 cm), the height of water filling in the water tank is preferably 1 cm higher than the platform, and the temperature of the water in the water tank is set at 22 °C.
  • Four icons of different shapes are pasted in the four directions of the maze arm as spatial positioning reference objects.
  • the platform was 1 cm below the water surface, and then the mice were put into the maze from two water entry points, and the mice were allowed to search for the platform for 60 seconds, and the standard of stopping the experiment was that the mice stayed on the platform for 10 seconds. If the mouse cannot find the platform within 60 seconds, guide it to the location of the platform and allow it to stay on the platform for 10 seconds.
  • mice were tested twice a day, and two different orientations were randomly selected to enter the water, and the interval between two experiments for each mouse was at least 1 hour.
  • the latency time (Latency to target) for the mice to find the platform was recorded for each experiment. 5 consecutive days of learning and training. On the 6th day, the platform was removed, and the platform test was carried out. The mouse was put into the water from the position of the diagonal line of the platform, and allowed to search freely in the water maze for 60 seconds, and the time when the mouse first arrived at the platform was recorded (Latency to target) and the time spent in the area (Time in zone).
  • Dp16 mice exhibited significant learning deficits during water maze training.
  • FIG 5D in the platform test, compared with WT mice, Dp16 mice took longer to reach the platform for the first time, and after knocking out B2m, Dp16 was significantly shortened; B2m +/- mice first reached the platform time.
  • Figure 5E in the platform test, compared with WT mice, Dp16 mice spent less time on the platform, while knockdown of B2m significantly increased the time of Dp16; B2m +/– mice on the platform. Compared with WT mice, there was no significant difference in the learning and memory abilities of B2m +/– mice.
  • the average swimming speed of Dp16 mice was significantly lower than that of WT mice, and the average swimming speed of Dp16;B2m +/ ⁇ mice was significantly increased relative to Dp16 mice.
  • Brain slice electrophysiological recordings were performed on WT, B2m +/– , Dp16, Dp16; B2m +/– mice aged 6-7 months. After the mice were anesthetized, the brain tissue was quickly removed and cooled in ice-cold and oxygenated artificial cerebrospinal fluid (ACSF), and then transferred to an oscillating microtome for coronal sectioning, with a thickness of 400 ⁇ m. The brain slices were incubated in oxygen-saturated ACSF at 32°C for 1 hour, and then transferred to room temperature for 1 hour. The recording electrodes were placed in the radiation layer of the CA1 region of the Schaffer collateral-commissural pathway, and the stimulating electrodes were placed in the CA3 region.
  • ACSF oxygenated artificial cerebrospinal fluid
  • the stimulation intensity was 30% of the maximum value of the field excitatory postsynaptic potential (fEPSP).
  • fEPSP field excitatory postsynaptic potential
  • the excitability/inhibition ratio (Excitation-Inhibition ratio, E/I ratio) of Dp16 mice was significantly lower than that of WT mice.
  • Dp16; B2m +/- mice E/I I ratio was significantly increased, suggesting that knocking out B2m can improve the excitatory/inhibitory balance in Down's mice.
  • the dendritic spine density of neurons was analyzed by Golgi staining, as shown in Figure 6E and Figure 6F, compared with WT mice, the dendritic spine density of neurons in Dp16 mice was significantly reduced, while knockdown of B2m significantly increased Dp16;B2m +/– dendritic spine density of neurons in the mouse brain.
  • Example 7 B2M protein in the brain of AD mice increases in an age-dependent manner, and colocalizes in A ⁇ amyloid plaques
  • the cerebral cortex tissues of 3, 6, 9, 12, and 15-month-old wild-type (WT) and Alzheimer's disease model mice The Jackson Laboratory, Cat. After tissue grinding and lysis, total protein was extracted, BCA concentration was measured, samples were prepared, and then immunoblotting was performed.
  • AAV adeno-associated virus
  • Example 8 Overexpression of B2M increases the deposition of A ⁇ amyloid plaques in the brains of AD mice
  • a ⁇ -ELISA detection is another method for detecting A ⁇ in the brain, which can quantitatively detect A ⁇ 1-42 in brain tissue per unit weight.
  • a ⁇ in the brain can be divided into two types: soluble and insoluble. Soluble A ⁇ refers to A ⁇ that can be dissolved in TBS and TBST solutions; insoluble A ⁇ refers to A ⁇ that needs to be treated with a stronger detergent, guanidine hydrochloride (GDN-HCl) to dissolve A ⁇ .
  • GDN-HCl guanidine hydrochloride
  • TBS and TBST solution to lyse the tissue sequentially, after incubation and centrifugation, take the supernatant as the soluble A ⁇ fraction; then use GDN-HCl solution to lyse the precipitate of the soluble fraction after centrifugation, after incubation and centrifugation, take the supernatant as the It is the insoluble A ⁇ component.
  • the BCA method was used to determine the total protein concentration, and the A ⁇ 1-42 ELISA kit (Thermo Fisher Scientific, Cat. No. KHB3441) was used to determine the A ⁇ 1-42 content.
  • B2M protein significantly increased the A ⁇ content and amyloid plaque deposition in the brain of 5 ⁇ FAD mice.
  • B2m knockout mice B2m +/– (The Jackson Laboratory, USA, Cat. No. 002087) were mated with 5 ⁇ FAD mice (The Jackson Laboratory, USA, Cat. No. 34840-JAX) to obtain 5 ⁇ FAD; B2m +/– mice, and then WT, B2m +/– , 5 ⁇ FAD, 5 ⁇ FAD; B2m +/– mice aged 6 to 7 months were subjected to behavioral tests related to learning and memory, including Morris water maze test and conditioned startle test.
  • mice Three days before the start of the experiment, touch and touch the mouse once a day, gently grasp the tail of the mouse to pick up the mouse, and let the mouse stay on the hand for 30 seconds; on the day of the experiment, transfer the experimental mouse to the prepared Allow the mice to acclimatize for 30 minutes. Animal behavior experiments at 9:00 every day
  • Morris water maze test (Morris water maze test) is carried out in a circular water tank (diameter 120 cm), the height of water filling in the water tank is preferably 1 cm higher than the platform, and the temperature of the water in the water tank is set at 22 °C.
  • Four icons of different shapes are pasted in the four directions of the maze arm as spatial positioning reference objects.
  • the platform was 1 cm below the water surface, and then the mice were put into the maze from two water entry points, and the mice were allowed to search for the platform for 60 seconds, and the standard of stopping the experiment was that the mice stayed on the platform for 10 seconds. If the mouse cannot find the platform within 60 seconds, guide it to the location of the platform and allow it to stay on the platform for 10 seconds.
  • mice were tested twice a day, and two different orientations were randomly selected to enter the water, and the interval between two experiments for each mouse was at least 1 hour.
  • the latency time (Latency to target) for the mice to find the platform was recorded for each experiment. 6 consecutive days of learning and training. On the 7th day, the platform was removed, and the platform test was carried out. The mice were put into the water from the position of the diagonal line of the platform, and allowed to search freely in the water maze for 60 seconds, and the time when the mice arrived at the platform area for the first time (Time to quadrant) and the number of mice crossing the platform area (Quadrant cross number).
  • Conditional panic test in the training process on the first day, the mice were placed in the test box, adapted to the environment for 2 minutes, and then the mice were given 60 decibels of noise stimulation (conditional stimulation) for 30 seconds, and The mice were given a 0.05 mA electric shock stimulus (unconditioned stimulus) in the last 2 seconds of the noise stimulus. Repeat three times with an interval of 60 seconds each time, and let the mice stay in the experimental box for 90 seconds after the last electric shock stimulation.
  • the contextual test was carried out. The mice were placed in the same test box for 5 minutes, and the percentage of freezing time (Freezing%) of the mice was recorded to measure the contextual memory.
  • Brain slice electrophysiological recordings were performed on WT, B2m +/– , 5 ⁇ FAD, 5 ⁇ FAD; B2m +/– mice aged 6-7 months. After the mice were anesthetized, the brain tissue was quickly removed and cooled in ice-cold and oxygenated artificial cerebrospinal fluid (ACSF), and then transferred to an oscillating microtome for coronal sectioning, with a thickness of 400 ⁇ m. The brain slices were incubated in oxygen-saturated ACSF at 32°C for 1 hour, and then transferred to room temperature for 1 hour. The recording electrodes were placed in the radiation layer of the CA1 region of the Schaffer collateral-commissural pathway, and the stimulating electrodes were placed in the CA3 region.
  • ACSF oxygenated artificial cerebrospinal fluid
  • the stimulation intensity was 30% of the maximum value of the field excitatory postsynaptic potential (fEPSP).
  • FEPS field excitatory postsynaptic potential
  • Fig. 10A-Fig. 10B compared with WT mice, the LTP of the Schaffer collateral-commissural pathway in the hippocampal CA3 to CA1 region of 5 ⁇ FAD mice was significantly impaired, while knockdown of B2m significantly enhanced 5 ⁇ FAD; B2m + /– LTP in mice, thus showing that knockdown of B2m reverses synaptic dysfunction in AD mice.
  • the density of neuronal dendritic spines was analyzed by Golgi staining, as shown in Figure 10C- Figure 10D, compared with WT mice, the density of neuronal dendritic spines in the brains of 5 ⁇ FAD mice was significantly reduced, while knockout B2m was significantly Increased dendritic spine density of neurons in 5 ⁇ FAD;B2m +/– mouse brains.
  • Example 11 Knockout of B2m reduces amyloid plaque deposition and microglia around the plaque in the brain of AD mice
  • Figure 11A to Figure 11C knockout of B2m +/– significantly reduced the number and area of A ⁇ amyloid plaques in the DG region of the hippocampus in the brains of 5 ⁇ FAD; B2m +/– mice .
  • a ⁇ 1-42 oligomerizes to form fibrillar oligomers, which subsequently deposit to form amyloid plaques.
  • the purified B2M protein was co-incubated with the A ⁇ 1-42 polypeptide at 37°C for 72 hours, then the samples were spotted on the carbon-coated grid, and then the samples were stained with 1% uranyl acetate, and passed through Hitachi HT-7800 Images were collected with a transmission electron microscope (Hitachi High-Tech, Japan). As shown in FIG. 11G , compared with the control group, the fibrillar oligomers formed after B2M protein incubation with A ⁇ 1-42 stained darker, that is, the oligomers were denser.
  • knocking out B2m can reduce the deposition of A ⁇ amyloid plaques and the number of microglial cells around the plaques in AD mice.
  • Antisense oligonucleotide refers to a 15-25bp short nucleic acid sequence complementary to a specific target RNA sequence. After the ASO sequence enters the cell, it binds to the target RNA through the principle of complementary base pairing, and increases or decreases the expression of the target gene through a variety of different mechanisms.
  • the synthetic B2M ASO sequence (final concentration: 50 nM) was transfected into human embryonic kidney cells HEK293T (US ATCC Company, catalog number CRL-3216) by Lipofectamine 2000 transfection reagent (Thermo Fisher Scientific Company, catalog number 11668019) for 48 hours After the cells were collected, the protein was extracted, the concentration was measured by BCA, and the sample was prepared for WB detection. As shown in Figure 12B to Figure 12E, ASO 1-9 targeting B2M can significantly reduce the expression of B2M protein in HEK293T cells.
  • ASO targeting human B2M can effectively reduce the expression of B2M in HEK293T cells.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Zoology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Physics & Mathematics (AREA)
  • Hematology (AREA)
  • Pathology (AREA)
  • Psychiatry (AREA)
  • Food Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Toxicology (AREA)
  • General Physics & Mathematics (AREA)
  • Plant Pathology (AREA)

Abstract

La présente invention concerne le domaine de la biomédecine, et concerne une utilisation pharmaceutique de β2-microglobuline ou d'un inhibiteur de celle-ci. En particulier, la présente invention concerne une utilisation de β2-microglobuline ou d'un inhibiteur de celle-ci dans la préparation d'un médicament pour le traitement et/ou la prévention du syndrome de Down ou de la maladie d'Alzheimer. La β2-microglobuline peut être utilisée en tant que cible d'un médicament efficace pour la prévention et le traitement du syndrome de Down ou de la maladie d'Alzheimer.
PCT/CN2022/097744 2021-06-16 2022-06-08 UTILISATION PHARMACEUTIQUE DE β2-MICROGLOBULINE OU D'UN INHIBITEUR DE CELLE-CI WO2022262624A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN202110665803.9 2021-06-16
CN202110665803.9A CN115475247B (zh) 2021-06-16 2021-06-16 β2-微球蛋白或其抑制剂的制药用途

Publications (1)

Publication Number Publication Date
WO2022262624A1 true WO2022262624A1 (fr) 2022-12-22

Family

ID=84418917

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2022/097744 WO2022262624A1 (fr) 2021-06-16 2022-06-08 UTILISATION PHARMACEUTIQUE DE β2-MICROGLOBULINE OU D'UN INHIBITEUR DE CELLE-CI

Country Status (2)

Country Link
CN (1) CN115475247B (fr)
WO (1) WO2022262624A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114807114A (zh) * 2022-04-14 2022-07-29 广州医科大学附属第二医院 一种记录果蝇大脑单细胞长时程增强电生理信号的方法

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1394549A1 (fr) * 2002-08-23 2004-03-03 Bayer HealthCare AG Biomarqueurs pour le diagnostic de la maladie d'Alzheimer
EP1741781A2 (fr) * 2002-02-20 2007-01-10 Sirna Therapeutics, Inc. Traitement de la maladie d'Alzheimer médié par l'interférence par l'ARN dans lequel il est fait appel à de petits fragments d'acides nucléiques interférants (siNA)
IN2008CN02923A (fr) * 2008-06-11 2009-03-06 Ac Immune Sa
WO2017127537A1 (fr) * 2016-01-19 2017-07-27 Thomas Blumenthal Biomarqueurs du syndrome de down et leurs utilisations
CN111358778A (zh) * 2020-03-17 2020-07-03 中国医科大学附属第一医院 Mcc950在制备预防或治疗阿尔茨海默病的药物中的应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA81216C2 (en) * 1999-06-01 2007-12-25 Prevention and treatment of amyloid disease
WO2008102199A1 (fr) * 2007-02-20 2008-08-28 Cellectis Variants de méganucléase clivant une séquence cible d'adn provenant du gène de la bêta-2-microglobuline et utilisations de ceux-ci
CA3088754A1 (fr) * 2018-01-22 2019-07-25 Liquid Biopsy Research LLC Methodes de detection de cancer du colon et de suivi de traitement
CN109738654B (zh) * 2019-01-29 2022-03-18 瑞博奥(广州)生物科技股份有限公司 β2-微球蛋白在制备用于定量检测肝癌标志物的试剂盒中的用途

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1741781A2 (fr) * 2002-02-20 2007-01-10 Sirna Therapeutics, Inc. Traitement de la maladie d'Alzheimer médié par l'interférence par l'ARN dans lequel il est fait appel à de petits fragments d'acides nucléiques interférants (siNA)
EP1394549A1 (fr) * 2002-08-23 2004-03-03 Bayer HealthCare AG Biomarqueurs pour le diagnostic de la maladie d'Alzheimer
IN2008CN02923A (fr) * 2008-06-11 2009-03-06 Ac Immune Sa
WO2017127537A1 (fr) * 2016-01-19 2017-07-27 Thomas Blumenthal Biomarqueurs du syndrome de down et leurs utilisations
CN111358778A (zh) * 2020-03-17 2020-07-03 中国医科大学附属第一医院 Mcc950在制备预防或治疗阿尔茨海默病的药物中的应用

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
DOMINICI ROBERTO, FINAZZI DARIO, POLITO LETIZIA, OLDONI EMANUELA, BUGARI GIOVANNA, MONTANELLI ALESSANDRO, SCARPINI ELIO, GALIMBERT: "2-microglobulin serum level between Alzheimer’s patients, cognitive healthy and mild cognitive impaired individuals", BIOMARKERS, TAYLOR AND FRANCIS, LONDON, GB, vol. 23, no. 6, 18 August 2018 (2018-08-18), GB , pages 603 - 608, XP093015693, ISSN: 1354-750X, DOI: 10.1080/1354750X.2018.1468825 *

Also Published As

Publication number Publication date
CN115475247A (zh) 2022-12-16
CN115475247B (zh) 2024-02-20

Similar Documents

Publication Publication Date Title
Blake et al. Utrophin: a structural and functional comparison to dystrophin
Kole et al. Activating transcription factor 3 (ATF3) protects retinal ganglion cells and promotes functional preservation after optic nerve crush
JP6772156B2 (ja) 治療用分子を選択する方法
Perronnet et al. Dystrophins, utrophins, and associated scaffolding complexes: role in mammalian brain and implications for therapeutic strategies
Kanwar et al. Simultaneous neuroprotection and blockade of inflammation reverses autoimmune encephalomyelitis
Kiuru-Enari et al. Hereditary gelsolin amyloidosis
US20110071088A1 (en) Method for treating neurological disorders
US20050152995A1 (en) Methods and compositions for promoting axon regeneration and cell replacement therapy
WO2022262624A1 (fr) UTILISATION PHARMACEUTIQUE DE β2-MICROGLOBULINE OU D'UN INHIBITEUR DE CELLE-CI
Gao et al. Identification of mesencephalic astrocyte-derived neurotrophic factor as a novel neuroprotective factor for retinal ganglion cells
de la Fuente et al. Calpain inhibition increases SMN protein in spinal cord motoneurons and ameliorates the spinal muscular atrophy phenotype in mice
Li et al. Dock3 participate in epileptogenesis through rac1 pathway in animal models
Han et al. Class I HDAC inhibitor improves synaptic proteins and repairs cytoskeleton through regulating synapse-related genes in vitro and in vivo
Nakamura et al. Modulation of both intrinsic and extrinsic factors additively promotes rewiring of corticospinal circuits after spinal cord injury
Faustini et al. Synapsin III gene silencing redeems alpha-synuclein transgenic mice from Parkinson's disease-like phenotype
Sen et al. Cytoskeleton saga: Its regulation in normal physiology and modulation in neurodegenerative disorders
WO2017180841A1 (fr) Traitement des malformations caverneuses cérébrales
US20080274077A1 (en) Method for Treating Neurological Disorders
CA3061296A1 (fr) Petites molecules organiques destinees a etre utilisees dans le traitement de troubles neuroinflammatoires
Zhang et al. Neuritin inhibits astrogliosis to ameliorate diabetic cognitive dysfunction
US20110124706A1 (en) SOCS3 Inhibition Promotes CNS Neuron Regeneration
Mich et al. AAV-mediated interneuron-specific gene replacement for Dravet syndrome
Wen et al. Complement-mediated synapse loss in Alzheimer’s disease: mechanisms and involvement of risk factors
Du et al. Visual recovery following optic nerve crush in male and female wild-type and TRIF-deficient mice
WO2023246847A1 (fr) Peptide bloquant b2m-glun1, composition pharmaceutique et son utilisation

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 22824104

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 22824104

Country of ref document: EP

Kind code of ref document: A1